Most of the developedvaccines against MERS are based on the application of different forms of theMERS-CoV glycoprotein (the full-length S, the S1 subunit, and RBD) [14, 15,16, 18, 22, 24, 47-55], which is themain target for neutralizing antibodies. This evidence concerns the gene ART4 and Middle East respiratory syndrome.